NCT06829329 is a Phase 2 clinical trial of AHB-137 in Chronic Hepatitis B, sponsored by Ausper Biopharma Co., Ltd..

Who is sponsoring NCT06829329?

NCT06829329 is sponsored by Ausper Biopharma Co., Ltd..

What drugs are being tested in NCT06829329?

Interventions in NCT06829329: AHB-137, NAs, Placebo.

What condition does NCT06829329 study?

NCT06829329 studies Chronic Hepatitis B.

Is NCT06829329 still recruiting?

NCT06829329 is currently active, enrolled. Last updated 1 May 2026.

Last reviewed 2026-05-01 · How we verify

NCT06829329

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With CHB

Active, enrolled Phase 2 Last updated 1 May 2026

What this trial tests

Phase 2 trial testing AHB-137 in Chronic Hepatitis B in 105 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

13 December 2024

Primary endpoint
2 August 2026

1 December 2026

Quick facts

Lead sponsor	Ausper Biopharma Co., Ltd.
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	105
Start date	13 December 2024
Primary completion	2 August 2026
Estimated completion	1 December 2026
Sites	4 locations across China

Drugs / interventions tested

AHB-137 — full drug profile →
NAs — full drug profile →
Placebo

Conditions studied

Chronic Hepatitis B — all drugs for Chronic Hepatitis B →

Sponsor

Ausper Biopharma Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Chronic Hepatitis B. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Proportion of participants achieving HBsAg lower than limit of detection (LOD) (0.05 IU/mL) and HBV DNA lower than lower limit of quantitation (LLOQ).
Time frame: Up to 24 weeks

Sponsor's own description

The study is to evaluate the efficacy and safety of AHB-137 in CHB participants. The total duration of the study, including screening phase, treatment phase and follow-up phase.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of AHB-137

Trials testing the same drug.

NCT07370207 — Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region · Phase 2 · recruiting
NCT07137910 — A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) · Phase 2 · not yet recruiting
NCT07246889 — Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) · Phase 3 · active not recruiting
NCT06993480 — A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatit · Phase 2 · recruiting
NCT07069569 — A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs · Phase 2 · active not recruiting

Other recruiting trials for Chronic Hepatitis B

Currently open trials in the same condition.

NCT07275918 — SA1211 Injection Phase 1 Study · Phase 1 · recruiting
NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
NCT07135349 — A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B · Phase 2 · active not recruiting
NCT07307586 — A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatiti · Phase 3 · recruiting
NCT07246889 — Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) · Phase 3 · active not recruiting

Other Ausper Biopharma Co., Ltd. trials

Trials by the same sponsor.

NCT07511218 — A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants · Phase 1 · not yet recruiting
NCT07137910 — A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) · Phase 2 · not yet recruiting
NCT07146100 — Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Inject · not yet recruiting
NCT07246889 — Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) · Phase 3 · active not recruiting
NCT06993480 — A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatit · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06829329 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ausper Biopharma Co., Ltd.
Last refreshed: 1 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06829329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing